【レポートの概要（一部）】
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 7
1.2 List of Figures 7
2 Introduction 8
2.1 What Is This Report About? 8
3 Definitions of Markets/Categories Covered 9
3.1 Drug Delivery Devices 9
3.1.1 Metered Dose Inhaler Devices 9
4 Company Snapshot 10
4.1 Key Facts 10
4.2 Company Overview 10
4.3 SWOT Snapshot 10
5 Business Description 11
5.1 Business Overview 11
5.2 Animal Health 11
5.2.1 Overview 11
5.2.2 Financials 11
5.2.3 Market View 11
5.3 Human Pharmaceuticals 12
5.3.1 Overview 12
5.3.2 Financials 12
5.3.3 Market View 12
5.4 Human Pharmaceuticals 12
5.4.1 Overview 12
5.4.2 Financials 12
5.4.3 Market View 12
5.5 Major Products and Services 13
5.5.1 Overview 13
6 History 15
7 Business Strategy 21
7.1 Mission Statement 21
8 SWOT Analysis 22
8.1 Overview 22
8.2 Boehringer Ingelheim GmbH Strengths 22
8.2.1 Delivering Value through Innovation 22
8.2.2 Geographical Diversity 23
8.2.3 Contract Manufacturing Capabilities 23
8.2.4 Broad Product Portfolio 23
8.3 Boehringer Ingelheim GmbH Weaknesses 24
8.3.1 Pradaxa Lawsuit 24
8.3.2 Product Recalls 24
8.4 Boehringer Ingelheim GmbH Opportunities 24
8.4.1 Strategic Alliances 24
8.4.2 Market Growth in Emerging Economies 24
8.4.3 Growing CRO Industry 25
8.5 Boehringer Ingelheim GmbH Threats 25
8.5.1 Increased Scrutiny on Imports 25
8.5.2 Stringent Government Regulations 25
8.5.3 Uncertain R&D Outcomes 25
8.5.4 Cost Containment Pressures 26
9 Competitors 27
10 Competitive Landscape 28
10.1 Drug Delivery Devices (Metered Dose Inhaler Devices), Global, Market Share (%), 2011 28
10.2 Boehringer Ingelheim GmbH, Market (Metered Dose Inhaler Devices), by Region, Market Share (2011) 29
10.3 Boehringer Ingelheim GmbH, Drug Delivery Devices (Metered Dose Inhaler Devices), by Country, Market Share (2011) 30
11 Key Employees 32
12 Key Employee Biographies 33
13 Company Statement 34
14 Locations And Subsidiaries 35
14.1 Head Office 35
14.2 Other Locations & Subsidiaries 35
15 Financial Deals Landscape 36
15.1 Boehringer Ingelheim GmbH, Deals Volume Summary, 2007 to YTD 2013 36
16 Boehringer Ingelheim GmbH Detailed Deal Summary 38
16.1 Partnerships 38
16.1.1 BioGenes Enters Into Co-Development Agreement With Boehringer Ingelheim 38
16.2 Equity Offering 39
16.2.1 Vectura Group Completes Private Placement Of $7.22 Million 39
16.2.2 Boehringer Ingelheim Completes Private Placement Of Bonds For $1,250.5 Million 40
17 Recent Developments 41
17.1 Strategy And Business Planning 41
17.1.1 Sep 17, 2012: Boehringer Ingelheim To ShutDown One API Plant In Petersburg, Virginia 41
17.1.2 Sep 10, 2012: Boehringer Ingelheim Implements Flexible Fully Disposable Up- And Downstream Manufacturing For Biopharmaceuticals 41
17.1.3 Jun 18, 2012: Boehringer Ingelheim Sets Up Distinctive Brand For Biopharmaceutical Contract Manufacturing Business 41
17.1.4 May 31, 2012: Boehringer Ingelheim Expands Development Capacities With New Technical Center 42
17.1.5 Mar 12, 2012: Boehringer Ingelheim Sets Up First Asian Veterinary Research & Development Center In Shanghai 42
17.1.6 Dec 14, 2011: Boehringer Ingelheim Significantly Expands Supply Center For China 43
17.1.7 Sep 26, 2011: Boehringer Ingelheim Expands Business With Biosimilars 44
17.1.8 Jun 20, 2011: Boehringer Ingelheim Expands New Service With New Fill And Finish Capabilities 44
17.1.9 Feb 15, 2011: Pfenex And Boehringer Ingelheim Sign Non-Exclusive Strategic Agreement For Use Of Pfenex Expression Technology 44
17.1.10 Nov 27, 2009: Boehringer Ingelheim, Vectura Terminate Collaboration 45
17.1.11 Nov 09, 2009: Evotec Extends Research Collaboration With Boehringer Ingelheim 45
17.1.12 Oct 22, 2009: Evotec Obtains E2.5m Milestone Payment From Boehringer Ingelheim 45
17.1.13 Jun 15, 2009: Boehringer Ingelheim, Vitae Collaborate For Development Of Beta-Secretase Inhibitors 46
17.1.14 May 29, 2009: Boehringer Ingelheim, DxS Sign Collaboration Agreement 46
17.1.15 Jun 17, 2008: Boehringer Ingelheim To Acquire Actimis Pharmaceuticals 46
17.1.16 Apr 19, 2006: Vectura Enters Agreement With Boehringer Ingelheim 47
17.2 Financial Announcements 48
17.2.1 Aug 14, 2012: Boehringer Ingelheim Achieves Growth In H1 2012 48
17.2.2 Apr 24, 2012: Boehringer Ingelheim Reports Net Sales Of €13.2 Billion In 2011 49
17.2.3 Aug 09, 2011: Boehringer Ingelheim Reports Net Sales Of €6.4 Billion For H1 2011 49
17.2.4 Jul 28, 2009: Boehringer Ingelheim Posts First Half Financial Results 50
17.2.5 Aug 07, 2008: Boehringer Reports 1H 2008 Results 51
17.2.6 Jul 26, 2007: Boehringer Declares H1 2007 Results 52
17.3 Research And Development 53
17.3.1 Sep 19, 2012: Ten Pharmaceutical Companies Unite To Accelerate Development Of New Medicines 53
17.3.2 Jul 09, 2012: Boehringer Ingelheim Establishes Translational Research Collaboration With Harvard University In Areas Of Unmet Medical Need 54
17.3.3 Feb 29, 2012: Boehringer Ingelheim Expands Capabilities In Biopharmaceutical Process Science 54
17.3.4 Feb 03, 2012: Boehringer Ingelheim, GWT And TU Dresden Sign Diabetes Research Collaboration 55
17.3.5 Jan 17, 2012: CompleGen Announces Successful Delivery Of XenoGene Technology To Boehringer Ingelheim Under Non-Exclusive Agreement 56
17.3.6 Jan 05, 2012: FORMA Therapeutics Announces Collaboration With Boehringer Ingelheim For Development Of New Oncology Drugs 56
17.3.7 Feb 16, 2011: Québec Consortium for Drug Discovery Launches New Explore Program To Drive Innovation 56
17.3.8 Nov 22, 2010: f-star And Boehringer Ingelheim Partner To Develop New Therapeutic Antibodies 57
17.3.9 Oct 26, 2010: Boehringer Ingelheim Partners With MacroGenics To Discover, Develop And Commercialize DART-Based Antibody Therapeutics 57
17.3.10 Aug 26, 2010: Boehringer Ingelheim Opens Center of Competence In Shanghai 58
17.4 Corporate Communications 59
17.4.1 Jun 26, 2008: Boehringer Ingelheim Announces Board Changes 59
17.5 Government and Public Interest 60
17.5.1 Sep 12, 2012: Common Application For HIV Patient Assistance Program Expedites Application Process For Lifesaving Drugs 60
17.5.2 Oct 23, 2009: EMEA Issues Positive Opinion For Micardis 61
17.5.3 Oct 14, 2009: Boehringer Ingelheim Receives Marketing Authorisation From European Commission For Mirapexin/Sifrol 61
17.5.4 Oct 07, 2009: Astellas, Boehringer Ingelheim Reach Settlement With Impax 62
17.6 Product News 62
17.6.1 Oct 01, 2012: Boehringer Ingelheim’s New Project Transfer Program Enables Fast Track To Launch For Biopharmaceuticals 62
17.7 Other Significant Developments 63
17.7.1 Oct 26, 2012: Boehringer Ingelheim To Invest €85m In Dortmund Facility To Double Respimat Production 63
17.7.2 Apr 25, 2012: Boehringer Ingelheim Standardizes All Prescription Medicine Commercial Teams Worldwide On Cloud-Based, Veeva CRM And iRep 63
17.7.3 Apr 20, 2012: Boehringer Ingelheim Launches GLORIA-AF Registry Program To Investigate Use Of Antithrombotic Therapy 64
17.7.4 Jan 26, 2012: Boehringer Ingelheim Launches Lean-to-Clinic Program For Fast Drug Product Supply 65
17.7.5 Oct 20, 2011: Patheon Signs Three Year $18m Development Agreement With Boehringer Ingelheim 65
18 Appendix 66
18.1 Research Methodology 67
18.2 Secondary Research 67
18.3 Primary Research 67
18.4 Models 68
18.5 Forecasts 68
18.6 Expert Panels 68
18.7 GlobalData Consulting 68
18.8 Currency Conversion 69
18.9 Contact Us 70
18.10 Disclaimer 70
【レポート販売概要】
■ タイトル：Boehringer Ingelheim GmbH：市場シェア分析■ 英文：Boehringer Ingelheim GmbH Market Share Analysis
■ 発行日：2013年1月31日
■ 調査会社：GlobalData
■ 商品コード：GDATA403160221
■ 調査対象地域：グローバル
- モバイルVAS市場、アプリケーション、機会（Mobile VAS Markets, Applications, and Opportunities: Applications, and Opportunities Third Edition）Mobile Value-added Service (VAS) applications represent a key aspect to the ongoing success of mobile network operators and everyone in the mobile communications value chain. With core services, such as bear voice and data communications becoming commodity offerings, wireless service providers are dependent on VAS applications to drive additional revenue and improved margins. This research represe …
- 音声通信モニタリングの世界市場予測Audio Communication Monitoring has become an important tool for businesses to remain competitive in the global market. The audio communication monitoring market has been segmented by various solutions and services, industry verticals and the major applications of audio communication monitoring. Audio communication monitoring providers play a vital role in assisting various organizations in quickly …
- トップ10モバイル技術の世界市場予測（～2022）：技術別（ブルートゥース、ウェアラブルテクノロジー、モバイル拡張現実、ワイヤレスギガビット、セルラーIoT、モバイルバイオメトリック、車車間通信および路車間通信V2X、一般家電品ワイヤレス充電）、地域別“Increasing demand for smart devices and technological advancements in wireless connectivity expected to drive the growth of the mobility technologies market during the forecast period”The Top 10 Mobility Technologies Market - Global Forecast to 2022, the market is expected to grow at a significant rate between 2016 and 2022. This report covers the major mobility technologies such as cellular IoT, …
- 化粧品保存料（防腐剤）の世界市場：合成防腐剤、天然防腐剤Global Cosmetic Preservatives Market: About this market Cosmetic preservatives can be defined as natural or synthetic ingredients that are used in the formulation of any cosmetic product to prevent product damage caused by microbial growth and increase the shelf life and product stability. Technavio’s cosmetic preservatives market analysis considers sales from both natural preservatives and synthe …
- 2014年戦略提言：Rubella診断検査市場The report presents a detailed analysis of the Rubella diagnostics market in the US, Europe, (France, Germany, Italy, Spain, UK) and Japan. Current scientific views on the Rubella definition, epidemiology and etiology are reviewed. The report provides the 5-year test volume and sales forecasts by country for the following market segments: - Hospitals - Commerc …
- 教育機関向けERPソリューションの世界市場The education ERP market continues to evolve and exhibits expansive growth in the years to come. ERP in education is not a new concept; ERPs were in full-fledged use in major corporations to ease the management process. The development of technology and widespread demand of computing concepts is currently driving the market for ERP in the education industry. This market is expected to grow substan …
- 機関車の世界市場：電力変換部品（整流器、インバーター、交流発電機、APU＆トラクションモーター）、技術（IGBTモジュール、GTOサイリスタモジュール＆SiCモジュール）、車両種類The locomotive market for power conversion systems is projected to grow at a CAGR of 2.92% during the forecast period, to reach a market size of USD 4.27 Billion by 2021. A wide array of upcoming rail projects, increased urbanization, and the rising demand for public transport has led to an increase in demand for locomotives and their related power conversion systems. Additionally technological ad …
- 自動車用アンチロールバーの世界市場：用途別、地域別Global Automotive Anti-roll Bar Market: About this market Technavio’s automotive anti-roll bar market analysis considers sales from both passenger cars and commercial vehicle applications. Our study also finds the sales of automotive anti-roll bar in APAC, Europe, MEA, North America, and South America. In 2019, the passenger car segment had a significant market share, and this trend is expected to …
- 救命救急用人工呼吸器の世界市場2019-2023About this market Growing chronic and surgical problems are increasing the demand for critical care ventilators. COPD is one of the major chronic respiratory problems, for which patient may need to get admitted in a critical care setting and would require critical care ventilators. Chronic diseases such as cancer are increasing globally. A cancer patient who require critical care treatment may get …
- 腹腔鏡器具の世界市場：腹腔鏡、注入器、エネルギー機器、吸気装置、閉鎖機器、手用器械The laparoscopic instruments market is expected to reach USD 11.68 Billion by in 2021 from USD 7.61 Billion in 2016, growing at a CAGR of 8.9%. The market is dominated by North America, followed by Europe, Asia-Pacific, and the Rest of the World (RoW). Asia-Pacific is expected to grow at the highest rate during the forecast period. The demand for laparoscopic instruments has been on the rise due t …
- がん診断の世界市場分析：タイプ別（臨床検査、遺伝検査、画像検査、内視鏡検査）、用途別（乳房、肺、肝臓、子宮頸、結腸直腸、皮膚）、地域別、セグメント予測、2014 – 2025The global cancer diagnostics market is expected to reach USD 232.7 billion by 2025, according to a new report by Grand View Research, Inc. Continual introduction of innovative products coupled with increasing need for early diagnosis of the disease is the prime factor driving the market growth. In addition, rapid growth of the sector is attributed to the penetration of technologically advanced la …
- dPCR（デジタルポリメラーゼ連鎖反応）の世界市場2017-2021ABSTRACTAbout dPCR Digital polymerase chain reaction (dPCR) technology is an advanced version of the polymerase chain reaction (PCR) technology that enables users to amplify and directly quantify nucleic acids, such as DNA, RNA, cDNA, and methylated DNA with a high level of precision. The technique allows users to statistically analyze PCR products by converting exponential, analog signals obtaine …
- 世界のLCDバックライトユニット市場動向（2012-2016）TechNavio's analysts forecast the Global LCD Backlight Unit market to grow at a CAGR of 3.52 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing popularity of flat panel displays. The Global LCD Backlight Unit market has also been witnessing increasing technological innovations. However, weak demand for LCDs could pose a challenge to the g …
- P-キシレン(PX)の世界市場予測P-xylene 2014 World Market Outlook and Forecast is an absolutely essential resource for anyone looking for detailed information on the mentioned market. Using a wide range of primary and secondary sources, we combined, analyzed and presented all available data about p-xylene market in the all-in-one report issued in a logical and easily accessible format. In addition to the analytical part, the re …
- バイオソリッドの世界市場2016-2020About Biosolids Sludge is a blend of liquid and solid wet mud-like components generated during the treatment of wastewater. It is viscous in nature. It contains water, natural materials, chemicals, and microorganisms including pathogens. The sludge produced by different industries include pollutants (heavy metals, pathogens, and organic pollutants) and compounds of agricultural value (organic wast …
